

Douglas B Evans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/339008/publications.pdf>

Version: 2024-02-01

147
papers

6,652
citations

126858

33
h-index

66879

78
g-index

149
all docs

149
docs citations

149
times ranked

7225
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Pancreatic ductal adenocarcinomas associated with intraductal papillary mucinous neoplasms (IPMNs) versus pseudo-IPMNs: relative frequency, clinicopathologic characteristics and differential diagnosis. <i>Modern Pathology</i> , 2022, 35, 96-105. | 2.9 | 13 |
| 2 | Selective Glucocorticoid Replacement Following Unilateral Adrenalectomy for Hypercortisolism and Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e538-e547. | 1.8 | 10 |
| 3 | Utility of Epinephrine Levels in Determining Adrenal Vein Cannulation During Adrenal Venous Sampling for Primary Aldosteronism. <i>Endocrine Practice</i> , 2022, 28, 276-281. | 1.1 | 7 |
| 4 | Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 275, e229-e237. | 2.1 | 14 |
| 5 | The Clinical Utility of Preoperative Thyroglobulin for Surgical Decision Making in Thyroid Disease. <i>Journal of Surgical Research</i> , 2022, 270, 230-235. | 0.8 | 3 |
| 6 | Reconstructing the tumor microenvironment to unlock therapeutic options in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 589-589. | 0.8 | 1 |
| 7 | Targeted therapy (TT) in patients with KRAS wildtype (WT) pancreatic ductal adenocarcinoma (PDAC) produces durable response.. <i>Journal of Clinical Oncology</i> , 2022, 40, 596-596. | 0.8 | 0 |
| 8 | Lessons learned from investigator-initiated clinical trials for localized pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2022, 125, 69-74. | 0.8 | 2 |
| 9 | Wide Variability in Catecholamine Levels From Adrenal Venous Sampling in Primary Aldosteronism. <i>Journal of Surgical Research</i> , 2022, 277, 1-6. | 0.8 | 2 |
| 10 | Variation in parathyroid adenoma size in patients with sporadic, primary hyperparathyroidism: small gland size does not preclude single gland disease. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 2067-2073. | 0.8 | 1 |
| 11 | MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in KRAS-mutated advanced pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16260-e16260. | 0.8 | 2 |
| 12 | Neoadjuvant radiation case volume and associated with margin-negative resection rates in patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16281-e16281. | 0.8 | 0 |
| 13 | Total Neoadjuvant Therapy for Operable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2246-2256. | 0.7 | 29 |
| 14 | Commentary: Surgery for locally advanced pancreatic cancer after neoadjuvant therapy. <i>Surgery</i> , 2021, 169, 1032-1033. | 1.0 | 3 |
| 15 | Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. <i>Surgery</i> , 2021, 169, 629-635. | 1.0 | 2 |
| 16 | Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. <i>Clinical Cancer Research</i> , 2021, 27, 226-236. | 3.2 | 15 |
| 17 | Impact of KRAS alterations in localized pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 431-431. | 0.8 | 0 |
| 18 | Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level. <i>Frontiers in Oncology</i> , 2021, 11, 606820. | 1.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer—Medical college of Wisconsin perspective. <i>Journal of Surgical Oncology</i> , 2021, 123, 1405-1413. | 0.8 | 4 |
| 20 | Precision Medicine for Pancreatic Cancer. <i>Advances in Oncology</i> , 2021, 1, 63-71. | 0.1 | 0 |
| 21 | Impact of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4136-4136. | 0.8 | 1 |
| 22 | Clinical outcomes in pancreatic ductal adenocarcinoma (PDAC) patients with underlying autoimmune disease (AID).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16233-e16233. | 0.8 | 0 |
| 23 | Confirmation of Feasibility of Selective Glucocorticoid Replacement Following Unilateral Adrenalectomy for Hypercortisolism and Primary Aldosteronism. <i>Journal of the Endocrine Society</i> , 2021, 5, A80-A81. | 0.1 | 1 |
| 24 | Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. <i>American Journal of Surgery</i> , 2021, 222, 10-17. | 0.9 | 41 |
| 25 | Tips for authors of surgical manuscripts from senior reviewers. <i>Surgery</i> , 2021, 170, 341-344. | 1.0 | 1 |
| 26 | EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 6135-6144. | 3.2 | 26 |
| 27 | An Institutional experience with primary hyperparathyroidism in the elderly over two decades. <i>American Journal of Surgery</i> , 2021, 222, 549-553. | 0.9 | 10 |
| 28 | Pancreaticoduodenectomy and Vascular Reconstruction. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 731-746. | 0.6 | 4 |
| 29 | Updates on the Management of Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, xvii-xviii. | 0.6 | 3 |
| 30 | Health Care Disparities and the Future of Pancreatic Cancer Care. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 759-771. | 0.6 | 8 |
| 31 | Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 879-889. | 2.7 | 2 |
| 32 | Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3773-3777. | 0.8 | 17 |
| 33 | Abstract PO-055: Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer. , 2021, , . | | 0 |
| 34 | Underdiagnosis of primary hyperparathyroidism in patients with osteoarthritis undergoing arthroplasty. <i>Surgery</i> , 2021, , . | 1.0 | 5 |
| 35 | Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. <i>Annals of Surgery</i> , 2020, 271, 740-747. | 2.1 | 127 |
| 36 | Confirmation of Parathyroid Tissue: Are Surgeons Aware of New and Novel Techniques?. <i>Journal of Surgical Research</i> , 2020, 246, 139-144. | 0.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Persistent/Recurrent Primary Hyperparathyroidism: Does the Number of Abnormal Glands Play a Role?. Journal of Surgical Research, 2020, 246, 335-341. | 0.8 | 26 |
| 38 | Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?. Journal of Gastrointestinal Surgery, 2020, 24, 235-242. | 0.9 | 6 |
| 39 | Treatment sequencing for pancreatic neuroendocrine tumors: daring to challenge the status quo. Journal of Gastrointestinal Oncology, 2020, 11, 545-547. | 0.6 | 1 |
| 40 | Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication. Journal of Gastrointestinal Oncology, 2020, 11, 548-558. | 0.6 | 18 |
| 41 | Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers. Hpb, 2020, 22, 1675-1685. | 0.1 | 10 |
| 42 | Locally advanced pancreatic cancer: staging, operability, and the importance of multimodality therapy. Hepatobiliary Surgery and Nutrition, 2020, 9, 497-500. | 0.7 | 3 |
| 43 | Perioperative Management and Outcomes of Hyperthyroid Patients Unable to Tolerate Antithyroid Drugs. World Journal of Surgery, 2020, 44, 3770-3777. | 0.8 | 5 |
| 44 | Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma. Annals of Diagnostic Pathology, 2020, 46, 151485. | 0.6 | 6 |
| 45 | Screening guidelines and recommendations for patients at high risk of developing endocrine cancers. Journal of Surgical Oncology, 2020, 121, 975-983. | 0.8 | 6 |
| 46 | Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 460. | 1.3 | 20 |
| 47 | Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. Hpb, 2020, 22, 1745-1752. | 0.1 | 2 |
| 48 | Utilization of somatic comprehensive genomic profiling (CGP) to identify patients (pts) with pancreatic cancer (PC) that harbor germline DNA damage repair (DDR) gene alterations.. Journal of Clinical Oncology, 2020, 38, 760-760. | 0.8 | 0 |
| 49 | Impact of CDKN2A/b status in pancreatic cancer (PC).. Journal of Clinical Oncology, 2020, 38, 759-759. | 0.8 | 0 |
| 50 | Perioperative Gemcitabine+ Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Annals of Surgical Oncology, 2019, 26, 4489-4497. | 0.7 | 19 |
| 51 | Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surgery, 2019, 166, 277-285. | 1.0 | 40 |
| 52 | Editorial: Small, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors: Observation becoming standard of care?. Surgery, 2019, 166, 164-165. | 1.0 | 2 |
| 53 | Distal splenorenal and mesocaval shunting at the time of pancreatectomy. Surgery, 2019, 165, 298-306. | 1.0 | 14 |
| 54 | A randomized, phase II clinical trial of preoperative stereotactic body radiation therapy versus conventionally fractionated chemoradiation for resectable, borderline-resectable, or locally advanced type a pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, TPS4167-TPS4167. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Locally advanced pancreas cancer: Staging and goals of therapy. <i>Surgery</i> , 2018, 163, 1053-1062. | 1.0 | 53 |
| 56 | Thyroid cancer in adolescents and young adults. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27025. | 0.8 | 39 |
| 57 | Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. <i>Abdominal Radiology</i> , 2018, 43, 351-363. | 1.0 | 11 |
| 58 | A Multi-Institutional Comparison of Adrenal Venous Sampling in Patients with Primary Aldosteronism: Caution Advised if Successful Bilateral Adrenal Vein Sampling is Not Achieved. <i>World Journal of Surgery</i> , 2018, 42, 466-472. | 0.8 | 18 |
| 59 | What Makes a Pancreatic Cancer Resectable?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 300-305. | 1.8 | 17 |
| 60 | Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls. <i>Thyroid</i> , 2018, 28, 1462-1467. | 2.4 | 19 |
| 61 | A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2018, 268, 610-619. | 2.1 | 58 |
| 62 | Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations. <i>Endocrine</i> , 2018, 61, 216-223. | 1.1 | 7 |
| 63 | Prophylactic Central Compartment Neck Dissection in Papillary Thyroid Cancer and Effect on Locoregional Recurrence. <i>Annals of Surgical Oncology</i> , 2018, 25, 2526-2534. | 0.7 | 73 |
| 64 | A postoperative parathyroid hormone-based algorithm to reduce symptomatic hypocalcemia following completion/total thyroidectomy: A retrospective analysis of 591 patients. <i>Surgery</i> , 2018, 164, 746-753. | 1.0 | 11 |
| 65 | Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. <i>BMC Cancer</i> , 2018, 18, 335. | 1.1 | 271 |
| 66 | Targeting of the Histone 3 Lysine 9 Methyltransferase Pathway in Kras-Induced Cell Growth and Pancreatic Cancer. <i>FASEB Journal</i> , 2018, 32, 826.11. | 0.2 | 0 |
| 67 | A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4112-4112. | 0.8 | 0 |
| 68 | Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. <i>Laboratory Investigation</i> , 2017, 97, 302-317. | 1.7 | 30 |
| 69 | Disparities in access to care and outcomes in patients with adrenocortical carcinoma. <i>Journal of Surgical Research</i> , 2017, 213, 138-146. | 0.8 | 10 |
| 70 | A Novel Reconstruction Technique During Pancreaticoduodenectomy After Roux-En-Y Gastric Bypass: How I do It. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1186-1191. | 0.9 | 3 |
| 71 | Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer?. <i>Practical Radiation Oncology</i> , 2017, 7, e449-e455. | 1.1 | 0 |
| 72 | Commentary on: Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study. <i>Surgery</i> , 2017, 161, 472-474. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Parathyroidectomy for primary hyperparathyroidism improves sleep quality: A prospective study. <i>Surgery</i> , 2017, 161, 25-34. | 1.0 | 15 |
| 74 | Using parathyroid hormone spikes during parathyroidectomy to guide intraoperative decision-making. <i>Journal of Surgical Research</i> , 2017, 209, 162-167. | 0.8 | 9 |
| 75 | Should functional renal scans be obtained prior to upper abdominal radiation for pancreatic cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, 442-442. | 0.8 | 0 |
| 76 | Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 282-282. | 0.8 | 0 |
| 77 | Prognostic value of positron emission tomography and preoperative CA19-9 in patients treated on a prospective phase II trial of neoadjuvant therapy and surgery.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15766-e15766. | 0.8 | 0 |
| 78 | Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. <i>Journal of Oncology Practice</i> , 2016, 12, 915-923. | 2.5 | 19 |
| 79 | Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2016, 114, 291-295. | 0.8 | 16 |
| 80 | Evolution of the Management of Resectable Pancreatic Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 772-778. | 2.5 | 24 |
| 81 | Response to comments on: Cosyntropin stimulation testing on postoperative day 1 allows for selective glucocorticoid replacement therapy following adrenalectomy for hypercortisolism: Results of a novel, multidisciplinary institutional protocol. <i>Surgery</i> , 2016, 160, 249-250. | 1.0 | 0 |
| 82 | Intraoperative exÂvivo parathyroid aspiration: A point-of-care test to confirm parathyroid tissue. <i>Surgery</i> , 2016, 160, 850-857. | 1.0 | 3 |
| 83 | Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?. <i>Journal of Surgical Oncology</i> , 2016, 114, 581-586. | 0.8 | 23 |
| 84 | Techniques of Vascular Resection and Reconstruction in Pancreatic Cancer. <i>Surgical Clinics of North America</i> , 2016, 96, 1351-1370. | 0.5 | 39 |
| 85 | Replaced gastroduodenal artery: Added benefit of the "artery first" approach during pancreaticoduodenectomy" A case report. <i>International Journal of Surgery Case Reports</i> , 2016, 23, 93-97. | 0.2 | 9 |
| 86 | Delayed Calcium Normalization After Presumed Curative Parathyroidectomy is Not Associated with the Development of Persistent or Recurrent Primary Hyperparathyroidism. <i>Annals of Surgical Oncology</i> , 2016, 23, 2310-2314. | 0.7 | 8 |
| 87 | Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Longâ€Term Survival. <i>World Journal of Surgery</i> , 2016, 40, 706-714. | 0.8 | 15 |
| 88 | Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. <i>Surgery</i> , 2016, 159, 893-900. | 1.0 | 114 |
| 89 | Association between body mass index and multigland primary hyperparathyroidism. <i>Journal of Surgical Research</i> , 2016, 202, 132-138. | 0.8 | 10 |
| 90 | Cosyntropin stimulation testing on postoperative day 1 allows for selective glucocorticoid replacement therapy after adrenalectomy for hypercortisolism: Results of a novel, multidisciplinary institutional protocol. <i>Surgery</i> , 2016, 159, 259-266. | 1.0 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Management of suspected adrenal metastases at 2 academic medical centers. American Journal of Surgery, 2016, 211, 664-670. | 0.9 | 18 |
| 92 | Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. JAMA Surgery, 2016, 151, 365. | 2.2 | 102 |
| 93 | Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. Annals of Surgical Oncology, 2016, 23, 134-141. | 0.7 | 76 |
| 94 | Analysis of an institutional protocol for thyroid lobectomy: Utility of routine intraoperative frozen section and expedited (overnight) pathology. Surgery, 2016, 159, 512-517. | 1.0 | 9 |
| 95 | Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence. Annals of Surgical Oncology, 2016, 23, 126-133. | 0.7 | 42 |
| 96 | Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine + nab-paclitaxel (NabG).. Journal of Clinical Oncology, 2016, 34, 397-397. | 0.8 | 5 |
| 97 | Can the sequence of chemotherapy regimens influence outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)?. Journal of Clinical Oncology, 2016, 34, 428-428. | 0.8 | 2 |
| 98 | Rapid immunohistochemical analysis of pancreatic cytology from endoscopic ultrasound-guided fine-needle aspirates: A prospective clinical trial.. Journal of Clinical Oncology, 2016, 34, 400-400. | 0.8 | 0 |
| 99 | Can response to treatment predict outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)?. Journal of Clinical Oncology, 2016, 34, 443-443. | 0.8 | 31 |
| 100 | Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2015, 112, 164-172. | 0.8 | 36 |
| 101 | Institutional experience with lateral neck dissections for thyroid cancer. Surgery, 2015, 158, 972-980. | 1.0 | 16 |
| 102 | Low 24-hour urine calcium levels in patients with sporadic primary hyperparathyroidism: is further evaluation warranted prior to parathyroidectomy?. American Journal of Surgery, 2015, 210, 123-128. | 0.9 | 4 |
| 103 | Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid, 2015, 25, 567-610. | 2.4 | 1,738 |
| 104 | The Effect of Thyroiditis on the Yield of Central Compartment Lymph Nodes in Patients with Papillary Thyroid Cancer. Annals of Surgical Oncology, 2015, 22, 4181-4186. | 0.7 | 12 |
| 105 | Neoadjuvant Therapy for Localized Pancreatic Cancer. Annals of Surgery, 2015, 261, 18-20. | 2.1 | 21 |
| 106 | Parathyroid Carcinoma: An Update on Treatment Outcomes and Prognostic Factors from the National Cancer Data Base (NCDB). Annals of Surgical Oncology, 2015, 22, 3990-3995. | 0.7 | 116 |
| 107 | Pancreatic Cancer Cell Migration and Metastasis Is Regulated by Chemokine-Biased Agonism and Bioenergetic Signaling. Cancer Research, 2015, 75, 3529-3542. | 0.4 | 56 |
| 108 | Central compartment lymph node dissection for differentiated thyroid cancer: review of the literature. International Journal of Endocrine Oncology, 2014, 1, 41-48. | 0.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 41-46. | 0.3 | 44 |
| 110 | Volume-Outcome in Cancer Surgery: Why has the Data Not Affected Policy Change?. <i>Annals of Surgical Oncology</i> , 2014, 21, 4056-4058. | 0.7 | 10 |
| 111 | Arterial resection at the time of pancreatectomy for cancer. <i>Surgery</i> , 2014, 155, 919-926. | 1.0 | 94 |
| 112 | A Single Parathyroid Hormone Level Obtained 4 Hours after Total Thyroidectomy Predicts the Need for Postoperative Calcium Supplementation. <i>Journal of the American College of Surgeons</i> , 2014, 219, 757-764. | 0.2 | 48 |
| 113 | Chemokines and chemokine receptors: Update on utility and challenges for the clinician. <i>Surgery</i> , 2014, 155, 961-973. | 1.0 | 55 |
| 114 | Neoadjuvant therapy for pancreatic cancer in patients older than age 75.. <i>Journal of Clinical Oncology</i> , 2014, 32, 287-287. | 0.8 | 8 |
| 115 | CXCL12 Chemokine Expression Suppresses Human Pancreatic Cancer Growth and Metastasis. <i>PLoS ONE</i> , 2014, 9, e90400. | 1.1 | 74 |
| 116 | Focused parathyroidectomy with intraoperative parathyroid hormone monitoring in patients with lithium-associated primary hyperparathyroidism. <i>Surgery</i> , 2013, 153, 718-722. | 1.0 | 16 |
| 117 | Association of decline in serum Ca19-9 after neoadjuvant therapy with improved survival among borderline resectable pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15082-e15082. | 0.8 | 2 |
| 118 | Local control in resectable and borderline resectable pancreatic cancer (PCa) treated with preoperative chemoradiation using IMRT or chemotherapy alone.. <i>Journal of Clinical Oncology</i> , 2013, 31, 282-282. | 0.8 | 0 |
| 119 | Phase II clinical trial of biomarker-directed therapy for localized pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4147-TPS4147. | 0.8 | 1 |
| 120 | Actionable targets in pancreatic cancer detected by immunohistochemistry (IHC), microarray (MA) fluorescent in situ hybridization (FISH), and mutational analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4013-4013. | 0.8 | 5 |
| 121 | Updated survival analysis of preoperative gemcitabine (gem) plus bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4051-4051. | 0.8 | 4 |
| 122 | 5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14613-e14613. | 0.8 | 9 |
| 123 | Papillary carcinoma of the thyroid: Balancing principles of oncology with emerging technology. <i>Surgery</i> , 2011, 150, 1015-1022. | 1.0 | 16 |
| 124 | Surgical Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement. <i>Annals of Surgical Oncology</i> , 2009, 16, 1736-1744. | 0.7 | 200 |
| 125 | Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head. <i>Journal of Clinical Oncology</i> , 2008, 26, 3496-3502. | 0.8 | 684 |
| 126 | Invited commentary: Medullary thyroid cancer: The importance of RET testing. <i>Surgery</i> , 2007, 141, 96-99. | 1.0 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Resectable pancreatic cancer: The role for neoadjuvant/preoperative therapy. <i>Hpb</i> , 2006, 8, 365-368. | 0.1 | 25 |
| 128 | Preoperative Chemoradiation for Pancreatic Cancer. <i>Seminars in Oncology</i> , 2005, 32, 25-29. | 0.8 | 15 |
| 129 | Diagnostic Accuracy of Endoscopic Ultrasound-Guided Fine-Needle Aspiration in Patients With Presumed Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2003, 7, 118-128. | 0.9 | 248 |
| 130 | Thyroid and adrenal cancer. , 2003, , 294-299. | | 0 |
| 131 | Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration. <i>Annals of Surgical Oncology</i> , 2001, 8, 123-132. | 0.7 | 326 |
| 132 | Phase I Study of Concomitant Gemcitabine and IMRT for Patients with Unresectable Adenocarcinoma of the Pancreatic Head. <i>International Journal of Gastrointestinal Cancer</i> , 2001, 30, 123-132. | 0.4 | 57 |
| 133 | Adrenal cortical carcinoma. <i>World Journal of Surgery</i> , 2001, 25, 914-926. | 0.8 | 295 |
| 134 | Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration. <i>Annals of Surgical Oncology</i> , 2001, 8, 123-132. | 0.7 | 94 |
| 135 | Thyroid Cancer: 1999 Update and Evaluation of Solitary Thyroid Nodules. <i>Annals of Surgical Oncology</i> , 2000, 7, 376-398. | 0.7 | 39 |
| 136 | Cost and Utilization Impact of a Clinical Pathway for Patients Undergoing Pancreaticoduodenectomy. <i>Annals of Surgical Oncology</i> , 2000, 7, 484-489. | 0.7 | 178 |
| 137 | Enrichment Methods for Mutation Detection. <i>Annals of the New York Academy of Sciences</i> , 2000, 906, 31-38. | 1.8 | 8 |
| 138 | Tumor Suppressor Gene Smad4/DPC4, Its Downstream Target Genes, and Regulation of Cell Cycle. <i>Annals of the New York Academy of Sciences</i> , 1999, 880, 31-37. | 1.8 | 27 |
| 139 | Chemoradiation for Localized Pancreatic Cancer: Another Perspective. <i>Annals of Surgical Oncology</i> , 1999, 6, 4-7. | 0.7 | 5 |
| 140 | Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 1998, 5, 242-250. | 2.0 | 37 |
| 141 | Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. <i>Annals of Surgical Oncology</i> , 1998, 5, 681-688. | 0.7 | 111 |
| 142 | Cell cycle regulation of human pancreatic cancer by tamoxifen. <i>Annals of Surgical Oncology</i> , 1998, 5, 342-349. | 0.7 | 17 |
| 143 | Molecular diagnosis of exocrine pancreatic cancer using a percutaneous technique. <i>Annals of Surgical Oncology</i> , 1996, 3, 241-246. | 0.7 | 21 |
| 144 | Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells. <i>International Journal of Gastrointestinal Cancer</i> , 1996, 19, 31-38. | 0.4 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | How I do it: Alternative method for exposure of the retropancreatic mesenteric vasculature during total pancreatectomy. , 1996, 61, 163-165. | | 32 |
| 146 | Preoperative chemoradiation for adenocarcinoma of the pancreas: M.D. Anderson experience. Journal of Surgical Oncology, 1995, 11, 132-140. | 1.4 | 6 |
| 147 | Neoadjuvant Treatment of Pancreatic Cancer: Borderline-Resectable Disease. , 0, , 727-740. | | 0 |